By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



65 Dowlin Forge Road

Exton  Pennsylvania  19341  U.S.A.
Phone: 610-363-3872 Fax: n/a



Company News
BioTrends Release: the Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis 5/2/2013 11:01:47 AM
BioTrends Release: ESAs and a New Class of Late Stage Oral HIF-PH Inhibitors May be Impacted by the Fact That Nephrologists Report Initiating ESAs at Lower Hemoglobins 4/4/2013 10:19:46 AM
BioTrends Release: Incorporation of the Anti-JC Virus Antibody Assay and Oral DMAs, Including Aubagio, are Top of Mind Recent Changes in the Management of Multiple Sclerosis Patients for Surveyed U.S. Neurologists 4/2/2013 1:06:14 PM
Two New Strategic Reports Expand Coverage of BioTrends's Biosimilars Advisory Service 4/1/2013 9:53:47 AM
BioTrends Release: Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists 3/26/2013 9:13:59 AM
BioTrends Release: U.S. Physicians Report Diabetic Nephropathy as the Renal Condition With the Highest Unmet Need for Treatment 3/14/2013 10:15:06 AM
BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND 3/14/2013 9:37:43 AM
Gastroenterologists Indicate They are Increasingly Using Biologics to Treat Patients with Crohn's Disease in Remission than They Were One Year Ago, According to a Recent BioTrends Report 3/6/2013 8:59:05 AM
BioTrends Release: EU5 Nephrologists Report a Decreasing Trend in the Treatment Prevalence of ESAs in the Haemodialysis Patient Population 2/7/2013 10:23:11 AM
BioTrends Release: EU5 Nephrologists Report a Stabilization of Phosphate Binder Treatment Prevalence in the Late-Stage CKD and Dialysis Patient Populations 2/5/2013 10:11:02 AM